Sanofi’s (SNY) R&D Track Record Remains Investor Concern, Says BofA

Group 1 - Sanofi (NASDAQ:SNY) is identified as one of the most oversold pharmaceutical stocks, with recent price target reductions from Citi and BofA [2][3] - BofA downgraded Sanofi from Buy to Neutral and lowered its price target from EUR 102 to EUR 92, citing concerns over the company's leadership transition and lack of pipeline triggers [2][3] - The appointment of Belén Garijo as the new CEO has raised investor concerns regarding the company's strategy reconstruction and past R&D failures [3] Group 2 - Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi-Aventis U.S. LLC, alleging illegal kickbacks to doctors to promote their medications [4][5] - The lawsuit highlights Sanofi's "Free Nurse Program" and "Support Services Program," which are claimed to violate the Texas Health Care Program Fraud Prevention Act [4][5] - The lawsuit seeks over $1 million in civil penalties and an injunction to prevent further illegal activities, raising concerns about the impact on patient care standards [5] Group 3 - Sanofi is a global pharmaceutical company focused on developing prescription medicines, vaccines, and consumer healthcare products, particularly in diabetes, cardiovascular, oncology, and rare diseases [6]